X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

By Guest Contributor  |    March 14, 2022
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

By Gabby Migliara  |    March 11, 2022
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...   Read More

Government price setting leaves behind families counting on new medicines

By Nicole Longo  |    February 23, 2022
Rather than pursuing policies that would actually address our broken insurance system and lower costs for patients – while protecting medical innovation – policymakers keep going back to the same,...   Read More

Government price setting won’t stop insurers from shifting costs to patients

By Nicole Longo  |    February 2, 2022
The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...   Read More

Guest post: Congress should not put future innovation at risk

By Guest Contributor  |    November 29, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

What is missing in the current drug pricing plan

By Brian Newell  |    November 23, 2021
A recent congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important...   Read More

In the current health care debate, Congress has lost sight of what matters to U.S. voters

By Debra DeShong  |    November 15, 2021
For months Congress has been debating massive changes to the nation’s social safety net, one of which is the highly popular Medicare prescription drug benefit. Unfortunately, much of what is being...   Read More

What they are saying: Government price setting for medicines is not the answer

By Sarah Sutton  |    November 4, 2021
America’s biopharmaceutical companies continue to voice the dangers of current proposals in Washington that would allow the government to set prices for medicines. While it’s being called government...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates